Glenmark’s deal with Harbour BioMed to make it richer by $120 million
Glenmark Pharmaceuticals S.A. and Harbour BioMed have entered into an exclusive license agreement for the Greater China territory to develop, manufacture and commercialize GBR 1302, Glenmark's bispecific antibody for cancer